SCHEMBL5865560

SCHEMBL5865560

FC(F)(F)c1cc(C(=C(Cl)Cl)c2ccc(Cl)cc2)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
ATM Q13315 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
NPFFR2 Q9Y5X5 1/20 0.47
KDR P35968 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
CNR2 P34972 1/20 0.42
TMPRSS4 Q9NRS4 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
PDK1 Q15118 1/20 0.41
HSD11B1 P28845 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865640 0.87 NPFFR2 (0.44) CYP3A4TSHRMAPK1ATML3MBTL1
SCHEMBL5865618 0.87 CYP3A4 (0.57) CYP3A4TSHRMAPK1ATML3MBTL1
SCHEMBL5865199 0.85 CYP3A4 (0.55) CYP3A4TSHRMAPK1ATML3MBTL1
SCHEMBL5865588 0.81 CYP3A4 (0.53) CYP3A4TSHRMAPK1ATML3MBTL1
SCHEMBL1794695 0.79 KDR (0.54) NPFFR2KDRTMPRSS4HTR3EHTR3B
SCHEMBL31542016 0.79 KDR (0.54) NPFFR2KDRTMPRSS4HTR3EHTR3B
SCHEMBL10656533 0.77 KDR (0.56) NPFFR2KDRHTR3EHTR3BHTR3A
Dichlorodiphenyldichloroethylene SCHEMBL177472 0.75 TSHR (1.00) CYP3A4TSHRMAPK1ATML3MBTL1
SCHEMBL375961 0.75 TSHR (0.59) TSHRNPFFR2KDRHTR3EHTR3B
SCHEMBL5865501 0.74 CYP3A4 (0.40) CYP3A4TSHRMAPK1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US disclosed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US disclosed
EP-1412311-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH Brandt, Ingvar (SE) 2004-04-28 EP disclosed
WO-2003002495-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH BRANDT INGVAR (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth NR3C2, NR5A1, NR3C1 CYP3A4 519/4885TSHR 118/4885MAPK1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.